Beyond fabrication, microfluidic lab-on-a-chip platforms recreate physiological and tumor-specific microenvironments, providing dynamic, real-time assessment of drug transport, metabolism, and tumorvascular interactions in biomimetic conditions that surpass conventional static models
They require balancing anticipated metabolic gains against timing constraints, discontinuation requirements, and residual uncertainty in reproductive outcomes
Initial loss in the first 4 weeks comes mostly from gastric effects
I always say that passion should not be the mediator, it should be the moderator
I assumed, perhaps naively, that if a licensed pharmacy was producing a medication, there would be evidence behind it